|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence, Mortality and
Prevalence Worldwide in 2012. IARC CancerBase No. 11 (Internet).
International Agency for Research on Cancer, Lyon, France.
2013.http://globocan.iarc.fr
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vincent TD, Steven AR and Theodore SL:
DeVita, Hellman and Rosenberg's Cancer: Principles & Practice
of Oncology. 9th. Wolters Kluwer Health/Lippincott Williams &
Wilkins; Philadelphia, PA: pp. 799–845. 2011
|
|
4
|
Lam KC and Mok TS: Targeted therapy: An
evolving world of lung cancer. Respirology. 16:13–21. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Braughler JM, Duncan LA and Chase RL: The
involvement of iron in lipid peroxidation. Importance of ferric to
ferrous ratios in initiation. J Biol Chem. 261:10282–10289.
1986.PubMed/NCBI
|
|
6
|
Cappuzzo F, Varella-Garcia M, Shigematsu
H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V,
Gregorc V, Toschi L, et al: Increased HER2 gene copy number is
associated with response to gefitinib therapy in epidermal growth
factor receptor-positive non-small-cell lung cancer patients. J
Clin Oncol. 23:5007–5018. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carter TA, Wodicka LM, Shah NP, Velasco
AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH III,
Edeen PT, et al: Inhibition of drug-resistant mutants of ABL KIT,
and EGF receptor kinases. Proc Natl Acad Sci USA. 102:pp.
11011–11016. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
8
|
D'Incecco A and Cappuzzo F: Gefitinib for
non-small-cell lung cancer treatment. Expert Opin Drug Saf.
10:987–996. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang F, Wang LD, Li B and Sheng ZX:
Gefitinib compared with systemic chemotherapy as first-line
treatment for chemotherapy-naive patients with advanced non-small
cell lung cancer: A meta-analysis of randomised controlled trials.
Clin Oncol(R Coll Radiol). 24:396–401. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duarte TL and Lunec J: Review: When is an
antioxidant not an antioxidant? A review of novel actions and
reactions of vitamin C. Free Radic Res. 39:671–686. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giordano CR, Mueller KL, Terlecky LJ,
Krentz KA, Bollig-Fischer A, Terlecky SR and Boerner JL: A targeted
enzyme approach to sensitization of tyrosine kinase
inhibitor-resistant breast cancer cells. Exp Cell Res.
318:2014–2021. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koptyra M, Falinski R, Nowicki MO,
Stoklosa T, Majsterek I, Nieborowska-Skorska M, Blasiak J and
Skorski T: BCR/ABL kinase induces self-mutagenesis via reactive
oxygen species to encode imatinib resistance. Blood. 108:319–327.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tartarone A and Lerose R: Clinical
approaches to treat patients with non-small cell lung cancer and
epidermal growth factor receptor tyrosine kinase inhibitor acquired
resistance. Ther Adv Respir Dis. 9:242–250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Russo A, Franchina T, Ricciardi GR, Picone
A, Ferraro G, Zanghì M, Toscano G, Giordano A and Adamo V: A decade
of EGFR inhibition in EGFR-mutated non small cell lung cancer
(NSCLC): Old successes and future perspectives. Oncotarget.
6:26814–26825. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang L and Fu L: Mechanisms of resistance
to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 5:390–401.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tan CS, Gilligan D and Pacey S: Treatment
approaches for EGFR-inhibitor-resistant patients with
non-small-cell lung cancer. Lancet Oncol. 16:e447–e459. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meves A, Stock SN, Beyerle A, Pittelkow MR
and Peus D: H(2)O(2) mediates oxidative stress-induced epidermal
growth factor receptor phosphorylation. Toxicol Lett. 122:205–214.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miller DM, Buettner GR and Aust SD:
Transition metals as catalysts of ‘autoxidation’ reactions. Free
Radic Biol Med. 8:95–108. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Monteiro HP, Ivaschenko Y, Fischer R and
Stern A: Ascorbic acid inhibits protein tyrosine phosphatases in
NIH 3T3 cells expressing human epidermal growth factor receptors.
Int J Biochem. 25:1859–1864. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37 Suppl 4:S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ono M, Hirata A, Kometani T, Miyagawa M,
Ueda S, Kinoshita H, Fujii T and Kuwano M: Sensitivity to gefitinib
(Iressa, ZD1839) in non-small cell lung cancer cell lines
correlates with dependence on the epidermal growth factor (EGF)
receptor/extracellular signal-regulated kinase 1/2 and EGF
receptor/Akt pathway for proliferation. Mol Cancer Ther. 3:465–472.
2004.PubMed/NCBI
|
|
24
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wenzel U, Nickel A, Kuntz S and Daniel H:
Ascorbic acid suppresses drug-induced apoptosis in human colon
cancer cells by scavenging mitochondrial superoxide anions.
Carcinogenesis. 25:703–712. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pal SK and Pegram M: Epidermal growth
factor receptor and signal transduction: Potential targets for
anti-cancer therapy. Anticancer Drugs. 16:483–494. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Petrelli F, Borgonovo K, Cabiddu M and
Barni S: Efficacy of EGFR tyrosine kinase inhibitors in patients
with EGFR-mutated non-small-cell lung cancer: A meta-analysis of 13
randomized trials. Clin Lung Cancer. 13:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Prasad KN and Kumar R: Effect of
individual and multiple antioxidant vitamins on growth and
morphology of human nontumorigenic and tumorigenic parotid acinar
cells in culture. Nutr Cancer. 26:11–19. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin Y, Wang X and Jin H: EGFR-TKI
resistance in NSCLC patients: Mechanisms and strategies. Am J
Cancer Res. 4:411–435. 2014.PubMed/NCBI
|
|
30
|
Collins L and Franzblau SG: Microplate
alamar blue assay versus BACTEC 460 system for high-throughput
screening of compounds against Mycobacterium tuberculosis and
Mycobacterium avium. Antimicrob Agents Chemother. 41:1004–1009.
1997.PubMed/NCBI
|
|
31
|
Tarumoto T, Nagai T, Ohmine K, Miyoshi T,
Nakamura M, Kondo T, Mitsugi K, Nakano S, Muroi K, Komatsu N and
Ozawa K: Ascorbic acid restores sensitivity to imatinib via
suppression of Nrf2-dependent gene expression in the
imatinib-resistant cell line. Exp Hematol. 32:375–381. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Prasad KN, Sinha PK, Ramanujam M and
Sakamoto A: Sodium ascorbate potentiates the growth inhibitory
effect of certain agents on neuroblastoma cells in culture. Proc
Natl Acad Sci USA. 76:pp. 829–832. 1979; View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pathak AK, Bhutani M, Guleria R, Bal S,
Mohan A, Mohanti BK, Sharma A, Pathak R, Bhardwaj NK, Prasad KN and
Kochupillai V: Chemotherapy alone vs. chemotherapy plus high dose
multiple antioxidants in patients with advanced non small cell lung
cancer. J Am Coll Nutr. 24:16–21. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sane AT, Cantin AM, Paquette B and Wagner
JR: Ascorbate modulation of H(2)O(2) and camptothecin-induced cell
death in Jurkat cells. Cancer Chemother Pharmacol. 54:315–321.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rhee SG: Cell signaling. H2O2, a necessary
evil for cell signaling. Science. 312:1882–1883. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rosell R, Ichinose Y, Taron M, Sarries C,
Queralt C, Mendez P, Sanchez JM, Nishiyama K, Moran T, Cirauqui B,
et al: Mutations in the tyrosine kinase domain of the EGFR gene
associated with gefitinib response in non-small-cell lung cancer.
Lung Cancer. 50:25–33. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sasazuki S, Hayashi T, Nakachi K, Sasaki
S, Tsubono Y, Okubo S, Hayashi M and Tsugane S: Protective effect
of vitamin C on oxidative stress: A randomized controlled trial.
Int J Vitam Nutr Res. 78:121–128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chakraborthy A, Ramani P, Sherlin HJ,
Premkumar P and Natesan A: Antioxidant and pro-oxidant activity of
Vitamin C in oral environment. Indian J Dent Res. 25:499–504. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Buettner GR and Jurkiewicz BA: Catalytic
metals, ascorbate and free radicals: Combinations to avoid. Radiat
Res. 145:532–541. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cieslak JA and Cullen JJ: Treatment of
pancreatic cancer with pharmacological ascorbate. Curr Pharm
Biotechnol. 16:759–770. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Miller VA, Kris MG, Shah N, Patel J,
Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, et al:
Bronchioloalveolar pathologic subtype and smoking history predict
sensitivity to gefitinib in advanced non-small-cell lung cancer. J
Clin Oncol. 22:1103–1109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Thomas CG, Vezyraki PE, Kalfakakou VP and
Evangelou AM: Vitamin C transiently arrests cancer cell cycle
progression inS phase and G2/M boundary by modulating the kinetics
of activation and the subcellular localization of Cdc25C
phosphatase. J Cell Physiol. 205:310–318. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leekha A, Gurjar BS, Tyagi A, Rizvi MA and
Verma AK: Vitamin C in synergism with cisplatin induces cell death
in cervical cancer cells through altered redox cycling and p53
upregulation. J Cancer Res Clin Oncol. 142:2503–2514. 2016.
View Article : Google Scholar : PubMed/NCBI
|
